Unlocking the potential of established products: toward new incentives rewarding innovation in Europe-Reference-Cited by-同舟云学术

Unlocking the potential of established products: toward new incentives rewarding innovation in Europe

Published:2017-01 Issue:1 Volume:5 Page:1298190
ISSN:2001-6689
Container-title:Journal of Market Access & Health Policy
language:en
Short-container-title:Journal of Market Access & Health Policy

Author:

Nayroles Gabrielle¹,Frybourg Sandrine²,Gabriel Sylvie¹,Kornfeld Åsa²,Antoñanzas-Villar Fernando³,Espín Jaime⁴,Jommi Claudio⁵⁶,Martini Nello⁷,de Pouvourville Gérard⁸,Tolley Keith⁹,Wasem Jürgen¹⁰,Toumi Mondher¹¹

Affiliation:

1. Global Market Access and Pricing, IPSEN Pharma, Boulogne-Billancourt, France

2. Pricing, Reimbursement and Market Access, Creativ-Ceutical, Paris, France

3. Department of Economy and Business, University of La Rioja, Logroño, Spain

4. Andalusian School of Public Health, Granada, Spain

5. Department of Pharmaceutical Sciences, University of Eastern Piedmont, Novara, Italy

6. Centre for Research on Health and Social Care Management (CERGAS), Bocconi University, Milan, Italy

7. Drugs & Health, Rome, Italy

8. Department of Economics, ESSEC Business School , Cergy-Pontoise, France

9. Tolley Health Economics Ltd, Buxton, UK

10. Department of Economics, University Duisburg-Essen, Essen, Germany

11. Department of Public Health, Aix-Marseille University, Marseille, France

Funder

IPSEN Pharma

Publisher

Informa UK Limited

Link

https://tandfonline.com/doi/pdf/10.1080/20016689.2017.1298190

Reference38 articles.

1. In this issue

2. The productivity crisis in pharmaceutical R&D

3. Off-label Prescribing Among Office-Based Physicians

4. Off-Label Prescribing: A Call for Heightened Professional and Government Oversight

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. New government drug repurposing programs: Opportunities and uncertainties;Science Translational Medicine;2024-06-26

2. New Drug-Development Paradigms? Opportunities and Uncertainties with New Government Drug Repurposing Programs;SSRN Electronic Journal;2024

3. COVID-19 off-label uses of medicines: the role of civil liability and regulation;The Geneva Papers on Risk and Insurance - Issues and Practice;2023-05-19

4. Old drugs, new tricks: Emerging role of drug repurposing in the management of atopic dermatitis;Cytokine & Growth Factor Reviews;2022-06

5. Relationships between developmental strategies for additional indications and price revisions for anticancer drugs in Japan;BMC Health Services Research;2021-12